OTC · Biotechnology

Brainstorm Cell Therapeutics Inc. (BCLI) Stock

$0.98 +6.52% OTC: BCLI Healthcare

Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies.

Valuation

MetricValue
Price$0.98
Market Cap$10.81M
P/E Ratio-1.04
P/B Ratio-0.98
P/S Ratio0.00
EPS (TTM)$-1.11
52-Week High$1.69
52-Week Low$0.46
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE109.21%
ROA-1000.00%
ROCE79.60%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.14
Current Ratio0.02

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-25.0M$-25.0M$-21.0M$-12.0M$-10.0M
Net Profit$-24.0M$-24.0M$-17.0M$12.0M$-10.0M
EPS$-10.09$-9.93$-4.48$2.19$-1.11
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$29.0M$8.0M$4.0M$2.0M$1.0M
Total Liabilities$10.0M$11.0M$9.0M$10.0M$11.0M
Cash$19.0M$1.0M$1.0M$0$0
Borrowings$5.0M$4.0M$1.0M$1.0M$0

Latest News

BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine PR Newswire · Jun 2, 2026 BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors PR Newswire · May 28, 2026 BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market PR Newswire · May 19, 2026 BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-26.0M$-19.0M$-20.0M$-9.0M$-7.0M
Investing Cash Flow$0$1.0M$2.0M$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-19.0M$-18.0M$1.0M$-1.0M$0
Free Cash Flow$-27.0M$-19.0M$-20.0M$-9.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-1.41
FCF Yield-61.62%
Quick Ratio0.02
Interest Coverage-110.00
Return 1Y37.31%
Return 3Y-96.55%
Return 5Y-98.19%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXP $1.40 -1.40% -0.36 $2.22M 0.00%
ADIL $3.33 +1.22% -1.14 $3.20M 0.00%
ADXNAddex Therapeutics Ltd $5.89 -0.17% -0.72 $4.24M 0.00%
BCDABioCardia, Inc. $0.84 -1.11% -0.83 $4.88M 0.00%
CDIO $1.62 +4.52% -0.53 $3.35M 0.00%

About Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.

Brainstorm Cell Therapeutics Inc. is headquartered in US.

Brainstorm Cell Therapeutics Inc. (BCLI) stock trades at $0.98 with a market capitalization of $10.81M. The stock is valued at a price-to-earnings (P/E) ratio of -1.04, price-to-book of -0.98, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.46 and $1.69, and currently trades 42.0% below its 52-week high.

On profitability, Brainstorm Cell Therapeutics Inc. generates a return on equity (ROE) of 109.21% — well above the market average, a sign of a high-quality business, return on capital employed of 79.60%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.brainstorm-cell.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides